# BONING UP ON OSTEOPOROSIS / Updates for pages 36 & 37 / May 2024

| Class/Drug Name | Brand Name | Form | Frequency | Gender |
|---|---|---|---|---|
| **ANTIRESORPTIVE AGENTS** | | | | |
| **Bisphosphonates** | | | | |
| Alendronate | Fosamax®, Fosamax® Plus D | Oral (Tablet, Solution) | Daily/Weekly | Women & Men |
| Alendronate | Binosto® | Oral (Effervescent Tablet) | Weekly | Women & Men |
| Ibandronate | Boniva® | Oral (Tablet) | Monthly | Women |
| Ibandronate | Boniva® | Intravenous (IV) Injection | Every 3 Months | Women |
| Risedronate | Actonel® | Oral (Tablet) | Daily/Weekly/Twice Monthly/Monthly | Women & Men |
| Risedronate | Atelvia® | Oral (Tablet) | Weekly | Women |
| Zoledronic Acid | Reclast® | Intravenous (IV) Infusion | Once A Year/Once Every Two Years | Women & Men |
| **RANK ligand (RANKL) inhibitor** | | | | |
| Denosumab | Prolia® | Injection | Every 6 months | Women & Men |
| Denosumab | Jubbonti® | Injection | Every 6 months | Women & Men |
| **Calcitonin** | | | | |
| Calcitonin | Fortical®, Miacalcin® | Nasal Spray | Daily | Women |
| Calcitonin | Miacalcin® | Injection | Varies | Women |
| **Estrogen* (Hormone Therapy)** | | | | |
| Estrogen | Multiple Brands | Oral (Tablet) | Daily | Women |
| Estrogen | Multiple Brands | Transdermal (Skin Patch) | Twice Weekly/ Weekly | Women |
| **Estrogen Agonist/Antagonist** *also called selective estrogen receptor modulators (SERMs)* | | | | |
| Raloxifene | Evista® | Oral (Tablet) | Daily | Women |
| **Tissue Specific Estrogen Complex (TSEC)** | | | | |
| Conjugated Estrogens/ Bazodoxifene | Duavee® | Oral (Tablet) | Daily | Women |
| **ANABOLIC AGENTS** | | | | |
| **Parathyroid Hormone (PTH) Analog** | | | | |
| Teriparatide | Bonsity® | Injection | Daily | Women & Men |
| Teriparatide | Forteo® | Injection | Daily | Women & Men |
| **Parathyroid Hormone-Related Protein (PTHrp) Analog** | | | | |
| Abaloparatide | Tymlos® | Injection | Daily | Women & Men |
| **Sclerostin Inhibitor** | | | | |
| Romosozumab-aqqg | Evenity® | Injection | 2 injections once monthly for 12 months | Women |

**Estrogen is also available in other preparations including a vaginal ring, cream, by injection and as an oral tablet taken sublingually (under the tongue). The vaginal preparations do not provide significant bone protection.*

## ANABOLIC MEDICINE: SCLEROSTIN INHIBITOR

### Romosozumab-aqqg (Brand Name Evenity®)

Romosozumab-aqqg is approved for:

- Treatment of osteoporosis in postmenopausal women at high risk for fracture defined as:
  - History of osteoporotic fracture
  - Multiple risk factors for fracture
  - Patients who have failed or are intolerant to other available osteoporosis therapy

Romosozumab-aqqg is a humanized monoclonal antibody (IgG2) produced in a mammalian cell line by recombinant DNA technology that binds to and inhibits sclerostin.

Romosozumab-aqqg is should be administered by a healthcare provider. Two separate subcutaneous injections, injected one after the other, are needed to administer the total dose of 210 mg. Injections should be administered once every month for 12 doses in the abdomen, thigh or upper arm.

The anabolic effect of Romosozumab-aqqg wanes after 12 monthly doses of therapy; therefore, you should limit use to 12 monthly doses. If osteoporosis therapy remains warranted, you should consider continued therapy with an anti-resorptive agent.

#### *Possible Side Effects of Romosozumab-aqqg Medicine*

Romosozumab-aqqg has a Boxed Warning in its product label, which advises that it may increase the risk of myocardial infarction (heart attack), stroke and cardiovascular death. Romosozumab-aqqg should not be initiated if you have had a heart attack or stroke within the preceding year. You and your healthcare provider should consider whether the benefits outweigh the risks if you have experienced other cardiovascular risk factors. If you experience a heart attack or stroke during therapy, it should be discontinued.

The most common adverse reactions reported with romosozumab-aqqg in clinical trials were arthralgia (joint pain) and headache. Hypersensitivity reactions (including angioedema, erythema multiforme, dermatitis, rash and urticaria) may also occur. Call your healthcare provider if you notice any abnormal skin-related symptoms.

ONJ and unusual fractures of the upper femur (thigh bone) may also occur while taking romosozumab-aqqg. Any groin or thigh discomfort or pain should be reported to your healthcare provider as well as any unhealed dental lesions. You should practice good dental care during treatment and should have an examination of the mouth by a doctor or dentist before starting the medicine.